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Diverse and signiﬁcant beneﬁts against cold/ﬂu symptoms and seasonal allergies have been observed with a dried fermentate
(DF) derived from Saccharomyces cerevisiae (EpiCor) in multiple published randomized trials. To determine if DF may inﬂuence
other immune conditions, two separate animal studies were conducted. Study 1 examined the ability of DF to prevent or reduce
inﬂammation when given orally for 14 days to rats prior to receiving 1% carrageenan (localized inﬂammation model). DF
signiﬁcantly(P<0.05)reducedswellingatalltimepoints(1,2,3,6,12,and24hours)versusthecontrol.EdemaseverityandPGE2
levels were reduced by approximately 50% and 25% (P<0.05), respectively. Study 2 examined the ability of DF to treat established
inﬂammation induced by type-2 collagen in mice over 4 weeks (autoimmune arthritis model). Signiﬁcantly reduced arthritis
scores, antibody response to type-2 collagen, and interferon-gamma levels were observed compared to controls (all parameters
P<0.05). DF favorably impacts multiple acute and potentially chronic immunologic inﬂammatory control mechanisms and
should be further tested in clinical trials.
1.Introduction
Concerns abound over the dearth of basic science and
clinical data with some prescription cold, allergy, and
other immune-based agents, which is highlighted by recent
concerns from the Food and Drug Administration (FDA)
and the subsequent removal of numerous products from
the market [1]. Issues and ambiguities with over-the-counter
( O T C )p r o d u c t sa p p e a rj u s ta sp r o b l e m a t i ca n dn e e dt ob e
monitored [2, 3]. Clinical and basic science research on the
eﬃcacy, safety, quality control, and mechanisms of action are
needed for any commercially available product.
The dried fermentate product (DF) derived from Saccha-
romycescerevisiae(EpiCor,Ankeny,IA)hasnowbeenstudied
inﬁverandomized,double-blind,placebo-controlledclinical
trials with over 300 adult participants [4–8]. The data
from these published trials suggest multiple mechanisms
of action compared to conventional and nonconventional
products. DF has demonstrated the potential to favorably
modulate immune responses without excessive suppression
or stimulation of overall immune activity. This conclusion
is based on multiple clinical observations in trials, which
also consistently demonstrated the safety of this product
(including minimal adverse events which were similar to
placebo). DF demonstrated signiﬁcant clinical beneﬁts in
reducing the incidence and duration of cold- and ﬂu-like
symptoms during fall and winter months, regardless of
inﬂuenza vaccination status [4, 5]. The daily consumption of
DF signiﬁcantly increased salivary IgA levels [6, 7] while at
the same time reducing pollen-associated allergy symptoms
such as nasal congestion during spring and summer months
[6].
Aninterventionthatcanimpactimmuneactivityinsome
capacity throughout the year might also be providing several
other subtle physiological beneﬁts. It remains a priority
to further elucidate these mechanisms of action based on
both laboratory research and clinical trial outcomes and
provide further clarity into the strengths and limitations of2 Evidence-Based Complementary and Alternative Medicine
DF. Thus, two well-established and accepted animal models
of immune surveillance were utilized that focus on anti-
inﬂammatory eﬀects of an intervention [9, 10]. The studies
were to determine if DF could either prevent (study 1) [9]o r
treat (study 2) [10] an induced inﬂammatory response.
2.MaterialsandMethods
2.1. Animal Care and Housing. All animal procedures for the
study wereapproved bythe Animal Care andUse Committee
of the University Council on Animal Care, University
of Western Ontario, London, Ontario, Canada and were
performed according to guidelines of the Canadian Council
on Animal Care. All animal procedures were performed
with the strictest adherence to these guidelines concerning
humane handling and treatment throughout the study and
included such items as ideal light and dark cycles (12 hours),
temperature (18–26 Celsius), relative humidity (30–70%),
and availability of food and water (ad libitum). Both the rats
and mice were randomized so that the variation in weight
in each group did not exceed two standard deviations of the
mean body weight.
2.2. DF Fermentate Preparation. EpiCor, which in this paper
is referred to as “DF,” was provided by the manufacturer of
the product (Embria Health Sciences, Ankeny, IA) as a pow-
der comprised of the heat-inactivated yeast Saccharomyces
cerevisiaeandthefermentationbrothmilieuthatwasutilized
for growth. DF was prepared weekly in a solution of 75%
glycerol and 25% deionized water to a ﬁnal concentration of
1mg/mL for oral gavage delivery. The volume administered
was adjusted to the mean body weight of each animal
group.
2.3. Study 1 Inﬂammation Prevention/Reduction Model. A
total of 20 Sprague-Dawley male rats (Charles River, Saint
Constant, QC), approximately 6–8 weeks of age at baseline,
were housed individually and acclimatized for one week
prior to the initiation of the study. After the acclimatization
period, the animals were weighed and randomly assigned
based on body weight using a computer-generated sequence
ensuring mean body weights were not statistically signiﬁcant
between groups. Animals were assigned to DF treatment
(n = 10) or control (n = 10) and were utilized for the
localized inﬂammatory prevention model. Rats ingested DF
( 7m g / k gb o d yw e i g h t )o rc o n t r o lb yo r a lg a v a g ef o r1 4d a y s .
After the treatment period (day 15), the left-hind footpads
were injected with 50μL of 1% carrageenan (saline diluted),
andtheright-hindfootpadswith50μLofsaline.Pawvolume
changesweremonitoredwithadigitalplethysmometer(IITC
LifeScience,Woodlands, CA) at baseline, 1, 2, 3, 6, 12, and 24
hours (end of the study period) after the injection. Approx-
imately, 100μL of blood was collected from the saphenous
vein of each rat prior to injection. The eﬀects of DF on
prostaglandin E2 (PGE2) and nerve growth factor (NGF)
concentrations in paw tissue in response to carrageenan and
saline injection were also measured. Rats were sacriﬁced
and paws removed and degloved. Tissue was transferred
into 50 volumes of ice-cold homogenization buﬀer and
homogenized by repeated cycles of 20-second ultrasonic
disruptionfollowedby10-secondrecovery.Thesecycleswere
continued until a homogenous slurry was produced using
an ultrasonic cell disruptor (Misonix, Farmingdale, NY).
The homogenization buﬀer contained 100mM Tris/HCl,
pH 7, 1M NaCl, 4mM EDTA.Na2, 2% Triton X-100, 2%
bovine serum albumin, 0.1% sodium azide, 5μg/mL apro-
tinin, 0.5μg/mL antipain, 157μg/mL benzamide, 0.1μg/mL
pepstatin A, and 17μg/mL phenylmethyl-sulfonyl ﬂuoride.
The homogenates were centrifuged at 14,000×gf o r3 0
minutes. The supernatants were transferred to microfuge
tubes and stored between −70 and −90 Celsius until analysis
for prostaglandin E2 (PGE2) and nerve growth factor (NGF)
by enzyme-linked immunosorbent assay (ELISA).
Tissue extracts and serum from the 6 time points from
each rat were analyzed for the presence of PGE2 using a
Prostaglandin E Metabolite kit (Cayman Chemicals, Cat.
514531, AnnArbor, MI).Theassaywasperformedaccording
to manufacturer’s protocol. Tissue extracts were diluted
1:640, and the serum samples were diluted 1:200 for the 0–
12-hour samples or 1:80 for 24-hour serum samples. PGE2
levels were expressed relative to wet tissue weight. Tissue
extracts were analyzed for the presence of NGF from each
rat using an NGF Emax ImmunoAssay kit (Promega, Cat.
G7630, Madison, WI). The assay was performed according
to manufacturer’s protocol. Tissue extracts were utilized
undilutedintheassay,andNGFlevelswereexpressedrelative
to wet tissue weight.
2.4. Study 2 Inﬂammation Treatment Model. A total of 20
DBA/1J male mice (The Jackson Laboratory, Bar Harbor,
ME), approximately 8–10 weeks of age at baseline, were
group housed and acclimatized for one week prior to the
initiation of the study. After the acclimatization period,
the animals were weighed and randomly assigned based on
body weight using a computer-generated sequence ensuring
mean body weights were not statistically signiﬁcant between
groups. Animals were assigned to DF treatment (n = 10)
or control (n = 10) and were utilized for the inﬂammation
treatment model. Mice were injected with type II collagen
(bovine collagen type II, Sigma catalog no. C1188, Oakville,
ON) at the base of the tail, and a booster injection
(intraperitoneal) of collagen was delivered 3 weeks after
the initial immunization. Upon appearance of arthritis (in
greater than 80%), mice were orally gavaged with either
DF (7mg/kg body weight in 75% glycerol) or control (75%
glycerol)dailyfor4weeks(endofthestudyperiod).Arthritis
was evaluated based on daily examination of erythema and
swelling (edema). A 0–4 scoring system was utilized and
monitored daily with 0 as no evidence of erythema and
swelling and 4 as the maximum amount comprising the
ankle, foot, and digits. The sum of the clinical scores of
the 4 paws yielded a sum score (maximum score of 16 for
each mouse). Swelling was monitored daily by measuring
ankle (medial/lateral) and tarsal (dorsal/ventral) thickness
with digital calipers. Blood was collected by saphenous
venipuncture at the onset of arthritis for the measurementEvidence-Based Complementary and Alternative Medicine 3
of anticollagen type II antibody. Cytokine levels (IFN-γ,
TNF, and IL-1β) were detected in mouse serum using
commercial ELISA kits (BD Biosciences; BD OptEIA Set
Mouse IFN gamma, Cat. 555138; BD OptEIA Set Mouse
TNF, Cat. 555268; BD OptEIA IL-1beta, cat. 559603, Becton
Dickenson, Mississauga, ON) and following manufacturer’s
instructions. ELISA plates were read on a MultiSkan Ascent
Plate Reader (Thermo Scientiﬁc, Middletown, VA), and data
were analyzed using Ascent Software, version 2.6.
2.5. Statistical Analysis. Analysis of body weights, arthritic
scores, cytokine data, and edema measurements was per-
formed using one-way analysis of variance (ANOVA) fol-
lowed by Holm-Sidak test. Signiﬁcance of both tests was
determined if P<0.05. Diﬀerences of means of NGF, PGE2,
and collagen antibody concentrations in serum and tissue
samples and diﬀerences of means for paw measurements
were analyzed using Student’s t-test.
3. Results
Study 1: Inﬂammation Prevention/Reduction Model. The
impact of a 14-day preventive treatment with DF compared
to controls was determined. The percentage changes in paw
volumes in the carrageenan, compared to the saline paws,
were signiﬁcantly diﬀerent (P<0.05), as was expected
from this model. The percentage change in paw volume
for the carrageenan-injected rats given DF compared to
vehicle was signiﬁcantly less (P<0.05) at all time points
(Figure 1). In the case of the vehicle and DF-treated saline-
injected rats, it is of interest to note that the inﬂammatory
response was less in the DF-treated rats at all time points,
although this was not statistically signiﬁcant. PGE2 in
paw tissue from carrageenan-injected rats was signiﬁcantly
(P<0.05) reduced for DF-fed compared to vehicle-
fed animals (Figure 2). Levels of PGE2 were lower in the
saline paws of DF-treated rats, but the results were not
signiﬁcantly diﬀerent. Though there was a decrease in PGE2
concentrations in the carrageenan-injected paws compared
to saline-injected paws of vehicle-fed rats, the diﬀerence
was not signiﬁcant. The increase in PGE2 concentration in
saline-injected paws is expected in vehicle-fed rats and may
be attributed to an inﬂammation resulting from the site of
injection. There was also a nonsigniﬁcant 22% reduction
in NGF levels in the DF group compared to the vehicle
group. NGF levels were signiﬁcantly lower (P<0.05) in
the saline compared to the carrageenan-injected paws in the
control group demonstrating the impact of this compound
on inducing increased levels of tissue NGF. No statistical
diﬀerences in the weights of the animals were observed
during the entire testing period (data not shown).
Study 2: Inﬂammation Treatment Model. The impact of
treatment with DF compared to controls after arthritis was
detected and conducted. The arthritis scores in the DF and
control arms were similar until day 17. A reduction in the
arthritic scores was observed between days 18 to 29 in the
DF-treated mice as compared to the control group. This
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Figure 1: Eﬀects of carrageenan injection on paw volumes in rats
pretreatedwithSaccharomycescerevisiaefermentate(DF)orvehicle.
The ﬁgure shows group means ± SEM for each time point. Asterisk
(∗) denotes a signiﬁcantly (P<0.05) lower percentage change in
paw volume for DF-fed rats compared to those on vehicle control.
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Figure 2: Eﬀects of carrageenan injection on PGE2 concentrations
(ng/gpawtissue)forSaccharomycescerevisiaefermentate-(DF-)fed
rats compared to vehicle-fed rats. The ﬁgure shows group means
± SD. Asterisk (∗) denotes a signiﬁcantly (P<0.05) lower PGE2
concentration in DF-fed rats compared to those on vehicle control.
reduction continued until the study termination, and the
scores in the DF mice were signiﬁcantly (P<0.05) lower
than the control mice (Figure 3). There was no diﬀerence
in antibody levels between DF treated and controls at the
onset of arthritis. DF treatment signiﬁcantly (P<0.05)
inhibited the antibody response to type 2 collagen compared
to controls by the end of the study (Figure 4).
No detectable concentrations of TNF or IL-1β were
found in the mice treated with the DF or controls. In
contrast, IFN-γ levels were signiﬁcantly (P<0.05) lower in
the DF group compared to controls at the end of the study
period (Figure 5). No statistical diﬀerences in the weights of
the animals were observed during the entire testing period.4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀect of treatment with Saccharomyces cerevisiae fer-
mentate (DF) or vehicle on the progression of the development
of arthritis. Treatment with DF decreased the severity of collagen-
induced arthritis between days 18 and 29 after the onset of arthritis
in >80% of the mice. Day 0 indicates the day of the booster
injection. Mice were gavaged daily with treatment or vehicle. The
ﬁgure shows group means ± SD for each time point. Asterisk (∗)
denotes a signiﬁcant (P<0.05) reduction in arthritis scores in DF-
gavaged mice compared to vehicle-gavaged mice.
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Figure 4: Antitype II collagen antibody titers in arthritic mice
treated with Saccharomyces cerevisiae fermentate (DF) or with
vehicle control. DF treatment blocked increases in antitype II
collagen antibody titers. The ﬁgure shows group means ± SEM.
Asterisk (∗) denotes a signiﬁcant (P<0.05) reduction in antitype
II collagen antibody titers in DF-gavaged mice compared to vehicle-
gavaged mice.
4. Discussion
DF consists of a dried powder of novel yeast fermentate
comprised of both the heat-inactivated yeast (Saccharomyces
cerevisiae)andthefermentationbrothinwhichitwasgrown.
This product contains a high concentration of metabolites
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Figure 5: IFN-γ levels in arthritic mice treated with Saccharomyces
cerevisiae fermentate (DF) or with vehicle control. The ﬁgure shows
group means ± SD. Asterisk (∗) denotes a signiﬁcant (P<0.05)
increase in IFN-γ levels in mice-gavaged vehicle compared to those
gavaged DF.
andnumerousanddiverse-freeradicalscavengercompounds
as exempliﬁed by its high antioxidant content as shown in
the oxygen radical absorbance capacity (ORAC) assay [11].
DF antioxidants have already demonstrated the ability to
gain access to live cells both in vivo and in vitro thereby
providing additional cellular protection [8, 12]. Further-
more, ﬁve randomized, double-blind, placebo-controlled
trials have demonstrated the eﬃcacy and safety of this
dietary supplement and have been published in peer-
reviewed journals [4–8]. Several mechanisms of action were
suggested from the clinical trials and in vitro studies, such
as enhanced salivary IgA production, NK cell activation, and
increased antioxidant capacity [6–8, 11, 12]. Still, further
mechanism of action research was needed to provide a
more lucid explanation of some of these observed clinical
beneﬁts as well as the potential for utilizing this product
for other immune-based conditions. A product that reduces
cold- and ﬂu-like symptoms and seasonal allergy symptoms
theoretically appears to provide both moderate immune
enhancing as well as moderate anti-inﬂammatory beneﬁts.
Studies1and2inthispaperwerecarriedouttoprovidemore
insight into possible anti-inﬂammatory properties of DF
in vivo.
The induction of paw swelling with carrageenan in study
1 was successful as expected, since this model has become
a standard for inﬂammation studies over time [9, 13].
However, the observation that DF signiﬁcantly reduced paw
swelling in this model at every time point was a consistent
positive and unexpected ﬁnding, suggesting an acute and
durable or potentially chronic response with DF. A greater
than 50% reduced swelling response was observed at all
but one time point after injection. A major mediator of
the localized inﬂammatory response in this model is the
proinﬂammatory prostaglandin PGE2 [14], which has a
role in other medical conditions as well. For example, in
autoimmunediseasessuchasrheumatoidarthritis,PGE2hasEvidence-Based Complementary and Alternative Medicine 5
a proinﬂammatory function [15]. The production of both
IL-23 and IL-17 is induced by PGE2, and these compounds
are implicated in rheumatoid and systemic joint destruction,
and perhaps even “wear and tear” localized joint osteoarthri-
tis [16, 17]. This study demonstrated a signiﬁcant reduc-
tion in carrageenan-induced tissue concentrations of PGE2,
which now provides some information into how DF may
be providing more speciﬁc immune beneﬁts. Prostaglandins,
including PGE2, are also produced in large amounts during
allergen exposure [18], and some conventional medicines
reduce PGE2 levels as part of their respective mechanisms
of action [19]. A signiﬁcant reduction in nasal congestion
from seasonal allergies found in a past clinical trial utilizing
DF can now be partially explained from the favorable impact
on PGE2 in this study [6]. It is also of interest that a
traditional Chinese medicine (Guizhi-Tang or GZT) utilized
to treat the common cold, pyrexia, and inﬂuenza is thought
to favorably impact several immune pathways including the
fairly recent ﬁnding of a reduction in PGE2 [20]. This
medicine also contains a plethora of diverse compounds
[21]. These observations may provide a partial explanation
of the favorable eﬀects with DF in signiﬁcantly reducing
the duration and incidence of cold and ﬂu symptoms in
clinical trials of vaccinated and nonvaccinated individuals
[4, 5].
Increases in NGF are associated with discomfort and
pain with inﬂammatory responses because it impacts mast
cells and aﬀerent neurons [9, 22]. The excessive production
of NGF found in past studies of allergic rhinitis patients
is again of interest [23, 24], because one of our past
DF clinical trials provided tangible symptomatic beneﬁts
against this condition [6]. Recent research has also sug-
gested that a mechanistic route for a future eﬃcacious
pain ameliorating medication may be via an anti-NGF
mechanism [25, 26] .N G Fi ss u c hap r o f o u n dp r i m a r y
mediator of chronic pain that even vaccine research has been
initiated in this area of medicine [27]. The moderate but
signiﬁcantreductioninNGFobservedinourstudyinDF-fed
rats with carrageenan-injected paws compared to controls
may be another explanation for the immune modulating
impact of DF. Yet, it must be kept in mind that NGF
also appears to inhibit immune suppressive signaling and
promotes temporary steroid receptor insensitivity in some
leukocytes [28–30]. In other words, again the interplay of
multiple compounds involved in immune activity suggests
that modulation rather than excessive reduction or stimu-
lation would explain some of the clinical ﬁndings with DF
[4–8].
Study 2 utilized the type II collagen-induced inﬂamma-
tory (arthritis) mouse model that has also been widely used
as a standard autoimmunity model [31]. Collagen injection
rapidly induces arthritic-like symptoms with associated
changes including swelling, erythema, and discomfort. Cel-
lular and humoral arms of the immune response to collagen
both contribute to inﬂammation via disease-exacerbating
proinﬂammatory cytokines and growth factors [32]. In this
study, the arthritis scores in the DF and control arms were
similar until day 17. However, by the end of the study period,
the scores were signiﬁcantly lower in the DF mice compared
to the controls. These tangible results were potentially
further strengthened with the observation of a signiﬁcant
reduction in the anticollagen type 2 antibody titers and IFN-
γ concentrations, which also suggests a potential modulation
of Th1 subsets of T helper cells [33].
IFN-γ is one of the primary endogenous mediators of
inﬂammation and immunity [34, 35]. IFN-γ has a diverse
role including macrophage activation, tissue remodeling,
host defense, and even enhancement of autoimmunity.
Classic autoimmune conditions such as inﬂammatory bowel
disease, lupus, multiple sclerosis, psoriasis, and rheumatoid
arthritis display large concentrations of activated macropha-
g e sa ti n ﬂ a m m a t o rys i t e s .T h e s em a c r o p h a g e sa r eb e l i e v e dt o
enhance the production of cytokines such as IL-6 and TNF.
Hence, IFN-γ has been considered an autoimmune disease
promoting or proinﬂammatory cytokine, as also suggested
from the collagen-induced arthritis model. However, the
complexity and diversity of the immune system and DF
for that matter is greater than previously appreciated. IFN-
γ is now thought to have pleiotropic eﬀects and thus can
have both promoting and suppressive roles in autoimmunity
[36]. For example, in a previous study [8], feeding DF to
human subjects caused a rapid but transient increase in
IFN-γ. Regardless, the moderate but signiﬁcant ability of
DF to suppress IFN-γ in study 2 appears to suggest one
favorable anti-inﬂammatory pathway, and perhaps any fur-
ther suppression would not necessarily suggest an enhanced
positive outcome without some negative consequences. This
supports a selective action of DF, dependent on the health
of the mammal and the timing of the sampling. This
again can be related to clinical studies whereby DF was
clinicallybeneﬁcialbutwithoutadverseeventscomparedtoa
placebo.
The limitations of these 2 studies were primarily the
one-time end-of-study biomarker measurements. Blood
sampling in the early to midphase of disease development
would be prudent; however, adhering to strict ethical animal
guidelines allows for a limited amount of blood to be drawn
from each mouse or rat, so only the end-of-study points
were feasible. TNF and IL-1β did not change appreciably
in DF treated or control, which would suggest that these
are not suitable markers for ongoing work with DF, and
perhaps measuring IL-6 would have been more informative
from a collective examination of past animal models [37].
Regardless, models of inﬂammation have long demonstrated
that a collective series of cytokines can potentially be
increased during inﬂammation, but not necessarily multiple
ones for any single model [38]. It is for this reason that two
separate studies seemed more logical to determine further
mechanistic insights into past and future clinical studies. Yet,
the complexities of the immune system and the ability of
numerous compounds to have bidirectional roles in speciﬁc
disease activity are daunting and will always represent a
limitation with this kind of basic science investigation [39,
40]. Regardless, the sheer number of clinical studies and
in vitro mechanism of action work on DF at this point
appears, in our opinion, to have hopefully established a
positive paradigm in the ﬁeld of immune modulating dietary
supplements.6 Evidence-Based Complementary and Alternative Medicine
5. Conclusions
The combined positive results of studies 1 and 2 suggest that
DF may act by modulating multiple acute and potentially
chronic immunologic and inﬂammatory control mecha-
nisms. These ﬁndings add to the clinical observations in
the ﬁve previous randomized trials and perhaps suggest
eﬃcacy in other areas of immune support. Further clinical
and laboratory research should be conducted to better
understand the areas where DF may continue to provide
beneﬁcial clinical results.
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